Research location
Oceanside
California, United States
Advertisement
Research activity in Oceanside
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 324 trials and 332 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Oceanside
324 linked trials · page 2 of 7Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaNCT05182476 · 2021-12-07 · 1 site observation
TERMINATED
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaNCT05110157 · 2021-11-29 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation
COMPLETED
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)NCT05103332 · 2021-11-05 · 1 site observation
COMPLETED
An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation
COMPLETED
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT04985942 · 2021-07-30 · 1 site observation
COMPLETED
A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive DisorderNCT04969510 · 2021-06-24 · 1 site observation
COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)NCT04820309 · 2021-06-02 · 3 site observations
COMPLETED
A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation
COMPLETED
Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715 · 2020-12-31 · 1 site observation
COMPLETED
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderNCT04476030 · 2020-11-09 · 1 site observation
COMPLETED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantNCT04533529 · 2020-09-16 · 1 site observation
COMPLETED
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyNCT04532749 · 2020-09-15 · 1 site observation
TERMINATED
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403 · 2020-09-09 · 1 site observation
COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeNCT04408755 · 2020-07-13 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)NCT04442503 · 2020-06-08 · 1 site observation
COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderNCT04285515 · 2020-02-27 · 1 site observation
COMPLETED
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic MedicationsNCT03818256 · 2019-12-04 · 1 site observation
COMPLETED
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.NCT04115319 · 2019-11-21 · 1 site observation
COMPLETED
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · 2019-09-05 · 1 site observation
COMPLETED
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367 · 2019-08-06 · 1 site observation
TERMINATED
Open-Label Safety Study of AXS-05 in Subjects With DepressionNCT04039022 · 2019-07-08 · 1 site observation
COMPLETED
A Trial of AXS-05 in Patients With Major Depressive DisorderNCT04019704 · 2019-06-20 · 1 site observation
COMPLETED
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®NCT03892889 · 2019-04-29 · 1 site observation
TERMINATED
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaNCT03893825 · 2019-04-17 · 1 site observation
COMPLETED
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)NCT03919994 · 2019-03-28 · 1 site observation
COMPLETED
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)NCT03864614 · 2019-02-27 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaNCT03896945 · 2019-02-15 · 1 site observation
TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaNCT03771664 · 2019-02-04 · 1 site observation
TERMINATED
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's DiseaseNCT03486938 · 2018-12-13 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175 · 2018-11-19 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)NCT03745820 · 2018-11-15 · 1 site observation
COMPLETED
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03739203 · 2018-11-10 · 2 site observations
COMPLETED
Home-Based Fluid Status Monitoring in Heart Failure PatientsNCT04013373 · 2018-10-09 · 1 site observation
TERMINATED
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid TumorsNCT03662204 · 2018-08-23 · 1 site observation
COMPLETED
A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)NCT03610048 · 2018-08-09 · 1 site observation
TERMINATED
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)NCT03614156 · 2018-08-02 · 1 site observation
TERMINATED
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaNCT03593213 · 2018-07-30 · 1 site observation
TERMINATED
Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderNCT03569475 · 2018-07-06 · 1 site observation
COMPLETED
Study of Rapastinel as Monotherapy in Patients With MDDNCT03560518 · 2018-06-15 · 1 site observation
TERMINATED
Zelquistinel in the Treatment of Major Depressive DisorderNCT03586427 · 2018-06-13 · 1 site observation
COMPLETED
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With SchizophreniaNCT03503318 · 2018-04-27 · 2 site observations
COMPLETED
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of SchizophreniaNCT03382639 · 2018-01-04 · 1 site observation
COMPLETED
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyNCT03321526 · 2017-12-12 · 1 site observation
COMPLETED
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 MonthsNCT03351244 · 2017-12-07 · 1 site observation
TERMINATED
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label TreatmentNCT03446001 · 2017-12-01 · 1 site observation
COMPLETED
Real-life Effectiveness of Vortioxetine in DepressionNCT03555136 · 2017-11-17 · 1 site observation
COMPLETED
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15 · 1 site observation
COMPLETED
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)NCT03188185 · 2017-06-12 · 1 site observation
COMPLETED
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With AlbuminuriaNCT03118739 · 2017-05-18 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.